Please assess the completion status of the following clinical trial:

Trial Title: Multi-Center Study of New Medications to Treat Vaginal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:~* Capable of providing written informed consent or assent~* Currently not menstruating and not anticipating menses during treatment~* If heterosexually active, subject must be post-menopausal for ≥ 1 year, surgically sterile, or practicing an acceptable form of birth control~* Negative pregnancy test~* Other criteria as identified in the protocol~Exclusion Criteria:~* Other infectious causes of vulvovaginitis~* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products~* Nursing mother~* Use of any investigational drug within 30 days of enrollment~* History of hypersensitivity to any ingredient/component of the formulations~* Other criteria as identified in the protocol

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terconazole vaginal gel (Type: ACTIVE_COMPARATOR): One applicator full at bedtime
- Gel vehicle (Type: PLACEBO_COMPARATOR): One applicator full at bedtime

Based on this trial design, predict the completion outcome and termination type (if applicable).